BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 33004905)

  • 41. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
    Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
    Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib.
    Hehlgans S; Booms P; Güllülü Ö; Sader R; Rödel C; Balermpas P; Rödel F; Ghanaati S
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142876
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy.
    Barker HE; Patel R; McLaughlin M; Schick U; Zaidi S; Nutting CM; Newbold KL; Bhide S; Harrington KJ
    Mol Cancer Ther; 2016 Sep; 15(9):2042-54. PubMed ID: 27422809
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress.
    Lindemann A; Patel AA; Tang L; Tanaka N; Gleber-Netto FO; Bartels MD; Wang L; McGrail DJ; Lin SY; Frank SJ; Frederick MJ; Myers JN; Osman AA
    Mol Cancer Ther; 2021 Jul; 20(7):1257-1269. PubMed ID: 33947685
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
    Michmerhuizen NL; Leonard E; Matovina C; Harris M; Herbst G; Kulkarni A; Zhai J; Jiang H; Carey TE; Brenner JC
    Mol Pharmacol; 2019 May; 95(5):528-536. PubMed ID: 30858165
    [TBL] [Abstract][Full Text] [Related]  

  • 46. β1 integrin mediates unresponsiveness to PI3Kα inhibition for radiochemosensitization of 3D HNSCC models.
    Korovina I; Elser M; Borodins O; Seifert M; Willers H; Cordes N
    Biomed Pharmacother; 2024 Feb; 171():116217. PubMed ID: 38286037
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacological Inhibition of HSP90 Radiosensitizes Head and Neck Squamous Cell Carcinoma Xenograft by Inhibition of DNA Damage Repair, Nucleotide Metabolism, and Radiation-Induced Tumor Vasculogenesis.
    Naz S; Leiker AJ; Choudhuri R; Preston O; Sowers AL; Gohain S; Gamson J; Mathias A; Van Waes C; Cook JA; Mitchell JB
    Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1295-1305. PubMed ID: 33838214
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phosphorylation of PI3K regulatory subunit p85 contributes to resistance against PI3K inhibitors in radioresistant head and neck cancer.
    Han MW; Ryu IS; Lee JC; Kim SH; Chang HW; Lee YS; Lee S; Kim SW; Kim SY
    Oral Oncol; 2018 Mar; 78():56-63. PubMed ID: 29496059
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacological PI3K inhibition in head and neck squamous cell carcinoma: A systematic review.
    Alves LB; Moura AC; Amorim Dos Santos J; Borges GA; Guerra ENS
    Toxicol In Vitro; 2023 Apr; 88():105558. PubMed ID: 36681288
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Simultaneously targeting ErbB family kinases and PI3K in HPV-positive head and neck squamous cell carcinoma.
    Yang Z; Liao J; Schumaker L; Carter-Cooper B; Lapidus RG; Fan X; Gaykalova DA; Mehra R; Cullen KJ; Dan H
    Oral Oncol; 2022 Aug; 131():105939. PubMed ID: 35667295
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The radiobiology of HPV-positive and HPV-negative head and neck squamous cell carcinoma.
    Zhou C; Parsons JL
    Expert Rev Mol Med; 2020 Jul; 22():e3. PubMed ID: 32611474
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.
    Anderson RT; Keysar SB; Bowles DW; Glogowska MJ; Astling DP; Morton JJ; Le P; Umpierrez A; Eagles-Soukup J; Gan GN; Vogler BW; Sehrt D; Takimoto SM; Aisner DL; Wilhelm F; Frederick BA; Varella-Garcia M; Tan AC; Jimeno A
    Mol Cancer Ther; 2013 Oct; 12(10):1994-2005. PubMed ID: 23873848
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long non-coding RNA HOTAIR/microRNA-206 sponge regulates STC2 and further influences cell biological functions in head and neck squamous cell carcinoma.
    Li T; Qin Y; Zhen Z; Shen H; Cong T; Schiferle E; Xiao S
    Cell Prolif; 2019 Sep; 52(5):e12651. PubMed ID: 31297902
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cucurbitacin I suppressed stem-like property and enhanced radiation-induced apoptosis in head and neck squamous carcinoma--derived CD44(+)ALDH1(+) cells.
    Chen YW; Chen KH; Huang PI; Chen YC; Chiou GY; Lo WL; Tseng LM; Hsu HS; Chang KW; Chiou SH
    Mol Cancer Ther; 2010 Nov; 9(11):2879-92. PubMed ID: 21062915
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Osthole induces cell cycle arrest and apoptosis in head and neck squamous cell carcinoma by suppressing the PI3K/AKT signaling pathway.
    Yang J; Zhu XJ; Jin MZ; Cao ZW; Ren YY; Gu ZW
    Chem Biol Interact; 2020 Jan; 316():108934. PubMed ID: 31870840
    [TBL] [Abstract][Full Text] [Related]  

  • 56. LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus-negative Head and Neck Squamous Cell Carcinoma.
    Yang L; Kumar B; Shen C; Zhao S; Blakaj D; Li T; Romito M; Teknos TN; Williams TM
    Mol Cancer Ther; 2019 Jun; 18(6):1025-1035. PubMed ID: 31015310
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PARP Inhibition Enhances Radiotherapy of SMAD4-Deficient Human Head and Neck Squamous Cell Carcinomas in Experimental Models.
    Hernandez AL; Young CD; Bian L; Weigel K; Nolan K; Frederick B; Han G; He G; Devon Trahan G; Rudolph MC; Jones KL; Oweida AJ; Karam SD; Raben D; Wang XJ
    Clin Cancer Res; 2020 Jun; 26(12):3058-3070. PubMed ID: 32139402
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular pathways in head and neck cancer: EGFR, PI3K, and more.
    Psyrri A; Seiwert TY; Jimeno A
    Am Soc Clin Oncol Educ Book; 2013; ():246-55. PubMed ID: 23714515
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.
    Brand TM; Hartmann S; Bhola NE; Li H; Zeng Y; O'Keefe RA; Ranall MV; Bandyopadhyay S; Soucheray M; Krogan NJ; Kemp C; Duvvuri U; LaVallee T; Johnson DE; Ozbun MA; Bauman JE; Grandis JR
    Cancer Res; 2018 May; 78(9):2383-2395. PubMed ID: 29440171
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.
    Kuger S; Flentje M; Djuzenova CS
    Radiat Oncol; 2015 Oct; 10():214. PubMed ID: 26498922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.